NEW YORK, December 20, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com monitors the most recent performances of four major players in the Drug Manufacturers space, namely: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). These companies belong to the Healthcare sector, which turned solidly lower in afternoon trade on Monday, December 19th, 2016, giving back prior gains. According to an article on NASDAQ, the NYSE Health Care Index fell about 0.4%, while shares of health care companies in the S&P 500 dropped nearly 0.5% as a group. You can access of our complimentary research reports on these stocks now at:
New York headquartered Bristol-Myers Squibb Co.'s shares rose 1.36%, closing Monday's trading session at $59.42. The stock recorded a trading volume of 8.36 million shares. The Company's shares have advanced 4.83% in the last month and 7.69% in the previous three months. The stock is trading 10.30% above its 50-day moving average. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 72.57.
On December 19th, 2016, Portola Pharmaceuticals Inc. announced that it has signed a $50 million loan agreement with Bristol-Myers Squibb and Pfizer Inc. that provides additional funding toward development and clinical studies of AndexXa™ (andexanet alfa), an investigational compound that is a potential antidote for Factor Xa inhibitors. Under terms of the agreement, Bristol-Myers Squibb and Pfizer will each loan Portola $25 million. The principal and interest will be repaid primarily through royalties on AndexXa commercial sales.
Yesterday, research firm Jefferies upgraded the Company's stock rating from 'Hold' to 'Buy'. Visit us today and download your complete report on BMY for free at:
On Monday, shares in London, the UK headquartered AstraZeneca PLC recorded a trading volume of 15.96 million shares, which was above their three months average volume of 6.79 million shares. The stock edged 3.27% lower, ending the day at $26.95. The Company's shares are trading below their 50-day moving average by 4.67%. Furthermore, shares of AstraZeneca, which engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide, have an RSI of 45.26.
On December 09th, 2016, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On December 19th, 2016, Ionis Pharmaceuticals, Inc. announced that it has advanced its lead drug candidate IONIS-AZ4-2.5-LRx, which has now been renamed AZD8233, into preclinical development. AZD8233 is designed to inhibit an undisclosed target to treat cardiovascular disease and is also the first of a new class of antisense drugs that uses both Ionis' proprietary Generation 2.5 chemistry and its LIgand Conjugated Antisense or LICA technology. In conjunction with this milestone, Ionis earned a $25 million milestone payment from AstraZeneca. The complimentary research report on AZN can be accessed at:
Indianapolis, Indiana headquartered Eli Lilly and Co.'s stock finished the day 0.15% higher at $73.42. A total volume of 6.09 million shares was traded, which was above their three months average volume of 5.89 million shares. The Company's shares are trading below their 50-day moving average by 0.60%. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 57.52.
On December 16th, 2016, Eli Lilly and Incyte Corp. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib - which if approved would be marketed as Olumiant®. This is the first regulatory step towards the approval of baricitinib and the CHMP positive opinion is now referred for final action to the European Commission, which grants approval in the EU.
On December 16th, 2016, research firm Morgan Stanley upgraded the Company's stock rating from 'Equal-Weight' to 'Overweight'. Register for free on Stock-Callers.com and download the PDF research report on LLY at:
Shares in Brentford, the UK headquartered GlaxoSmithKline PLC ended yesterday's session 0.60% lower at $38.31. The stock recorded a trading volume of 3.33 million shares. The Company's shares have advanced 1.56% on an YTD basis. The stock is trading 2.43% below its 50-day moving average. Moreover, shares of GlaxoSmithKline, which creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 47.94.
On December 19th, 2016, GlaxoSmithKline and Innoviva, Inc. announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to therapy with the once-daily dual combination therapy, Relvar/Breo® (FF/VI), as a treatment for patients with asthma. Get free access to your research report on GSK at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA